Skip to main content

This translation is provided for general access and has no recorded medical-language review.

Editorial general information — not a clinical-review record

Published: Updated: Publisher: Dr. Murat Toktamışoğlu

Why do causality assessment and a retained sample matter after an exosome adverse event?

After infection, marked inflammation or an unexpected tissue response to a product presented as exosomes or EVs, timing matters but does not prove cause. Product, procedure, co-treatment and health records should be preserved; a sample is meaningful only with valid storage and chain of custody.

This translation has no recorded clinical or medical-language review.

Direct answer

  • Necessary medical assessment and care take priority.
  • Opened vial, lot record, photographs, device settings and route are separate evidence components.
  • An unnamed residue stored under the wrong conditions may not yield a reliable laboratory result.

A timeline for causality

Place symptom onset, distribution and progression on the same timeline as product name, claimed source, lot, opening and administration time, dose, route, skin preparation and co-procedures such as laser or microneedling. New medicines, infection, allergy, other cosmetics and underlying disease may be alternative explanations. Their presence is not a reason to avoid reporting; it changes the strength of a causal assessment.

Sample and chain of custody

Quarantine unused same-lot product, an opened vial or packaging only under manufacturer instructions and local institutional procedure. Record who collected it, when, temperature, seal and each transfer. Arbitrary freezing, thawing or transfer into another container can compromise microbiology and particle analysis. Obtain clinical specimens needed for patient care separately from the product sample.

Limits of a test result

Select sterility, endotoxin, mycoplasma, identity or content testing for the question being investigated. One negative result does not prove the product safe, and one positive result does not automatically explain the entire clinical event. Reference methods and suitable controls matter. Add results to manufacturer and authority reports, explain the personal findings and follow-up plan, and preserve uncertainty where the evidence remains incomplete.

Scope of this article

This content is not diagnosis, prescribing, personal risk assessment or a treatment plan. Sources may be limited to a particular product, device, task, indication or study group.

Sources and evidence limits

These links are editorial starting points used to examine the article's boundaries.

  1. Microneedling for Facial Rejuvenation: A Systematic Review

    Foppiani JA et al. · 2025

    Scope and limitations: Interpret this source only within the exact product, device, method, indication and study population it names. It does not establish personal suitability, Turkish authorization, a universal protocol or a guaranteed outcome; consult the full source and current local information.

    Editorial source — not a signed clinical review

  2. Evaluating the Effectiveness and Safety of Radiofrequency for Face and Neck Rejuvenation: A Systematic Review

    Austin GK, Struble SL, Quatela VC · 2022

    Scope and limitations: Interpret this source only within the exact product, device, method, indication and study population it names. It does not establish personal suitability, Turkish authorization, a universal protocol or a guaranteed outcome; consult the full source and current local information.

    Editorial source — not a signed clinical review

  3. Energy-Based Devices for the Treatment of Facial Skin Conditions in Skin of Color

    Sanyal RD, Fabi SG · 2024

    Scope and limitations: Interpret this source only within the exact product, device, method, indication and study population it names. It does not establish personal suitability, Turkish authorization, a universal protocol or a guaranteed outcome; consult the full source and current local information.

    Editorial source — not a signed clinical review

  4. Potential Risks with Certain Uses of Radiofrequency (RF) Microneedling – FDA Safety Communication

    U.S. Food and Drug Administration (FDA) · 2025

    Scope and limitations: Interpret this source only within the exact product, device, method, indication and study population it names. It does not establish personal suitability, Turkish authorization, a universal protocol or a guaranteed outcome; consult the full source and current local information.

    Editorial source — not a signed clinical review

  5. A Systematic Review and Meta-Analysis of Efficacy, Safety, and Satisfaction Rates of Laser Combination Treatments vs Laser Monotherapy in Skin Rejuvenation Resurfacing

    Pour Mohammad A et al. · 2023

    Scope and limitations: Interpret this source only within the exact product, device, method, indication and study population it names. It does not establish personal suitability, Turkish authorization, a universal protocol or a guaranteed outcome; consult the full source and current local information.

    Editorial source — not a signed clinical review

  6. Outcomes and Adverse Effects of Ablative vs Nonablative Lasers for Skin Resurfacing: A Systematic Review of 1093 Patients

    Mirza HN, Mirza FN, Khatri KA · 2021

    Scope and limitations: Interpret this source only within the exact product, device, method, indication and study population it names. It does not establish personal suitability, Turkish authorization, a universal protocol or a guaranteed outcome; consult the full source and current local information.

    Editorial source — not a signed clinical review

  7. Medical Lasers

    U.S. Food and Drug Administration (FDA) · 2023

    Scope and limitations: Interpret this source only within the exact product, device, method, indication and study population it names. It does not establish personal suitability, Turkish authorization, a universal protocol or a guaranteed outcome; consult the full source and current local information.

    Editorial source — not a signed clinical review

  8. Public Safety Alert Due to Marketing of Unapproved Stem Cell and Exosome Products

    U.S. Food and Drug Administration (FDA) · 2019

    Scope and limitations: Interpret this source only within the exact product, device, method, indication and study population it names. It does not establish personal suitability, Turkish authorization, a universal protocol or a guaranteed outcome; consult the full source and current local information.

    Editorial source — not a signed clinical review

  9. Minimal Information for Studies of Extracellular Vesicles (MISEV2023): From Basic to Advanced Approaches

    International Society for Extracellular Vesicles consensus authors · 2024

    Scope and limitations: Interpret this source only within the exact product, device, method, indication and study population it names. It does not establish personal suitability, Turkish authorization, a universal protocol or a guaranteed outcome; consult the full source and current local information.

    Editorial source — not a signed clinical review

  10. Different Storage and Freezing Protocols for Extracellular Vesicles: A Systematic Review

    Systematic review authors · 2024

    Scope and limitations: Interpret this source only within the exact product, device, method, indication and study population it names. It does not establish personal suitability, Turkish authorization, a universal protocol or a guaranteed outcome; consult the full source and current local information.

    Editorial source — not a signed clinical review